Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
Final classification
VUS
c.266_267del
unknown
This variant

VUS: no criteria were met or applied, so no ACMG/AMP combination rule was satisfied.

Transcript
HGVS · transcript:coding
TP53:c.266_267del
GRCh38
GRCh37
Basis Insufficient evidence was available to apply any criterion, so no ACMG/AMP combination rule was met and the variant is classified as VUS.
Insufficient evidence was available to apply any criterion, so no ACMG/AMP combination rule was met and the variant is classified as VUS.
Classification rationale
VUS
c.266_267del unknown

VUS: no criteria were met or applied, so no ACMG/AMP combination rule was satisfied.

Applied criteria · 0 applied · 27 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 0

No criteria were applied for this variant.

Assessed · not applied · 0 not met · 27 not assessed
Pathogenic
PVS1 Not assessed: the transcript context could not be resolved, so whether this 2-bp deletion causes a frameshift that triggers nonsense-mediated decay could not be determined.
PS1 Not assessed: no established pathogenic variant with the same amino-acid change was identified, and this 2-bp deletion produces a frameshift, not a single amino-acid substitution.
PS2 Not assessed: no de novo occurrence evidence from proband and parental testing was available.
PS3 Not assessed: insufficient functional or validated-assay evidence was available to evaluate the variant's effect.
PS4 Not assessed: no case-control data with affected and control allele counts were available.
PM1 Not assessed: the protein position and domain context could not be resolved, so mutational hotspot or functional-domain status could not be evaluated.
PM2 Not assessed: no reliable population allele count or frequency was available, so absence from population databases could not be established.
PM3 Not assessed: no affected probands, segregation data, or documented pathogenic variant in trans were available.
PM4 Not assessed: without a resolved transcript consequence, whether this deletion is in-frame or frameshift could not be determined.
PM5 Not assessed: this 2-bp deletion causes a frameshift, not a missense substitution, so the classic same-residue PM5 comparison did not apply and no candidate was confirmed.
PM6 Not assessed: no clinical or family observation of an assumed de novo occurrence was available.
PP1 Not assessed: no segregation data from affected or unaffected relatives were available.
PP2 Not assessed: this is a 2-bp deletion, not a missense variant, so the missense-specific PP2 rule does not apply to it.
PP3 Not assessed: no calibrated computational prediction, splice or missense, was available for this 2-bp deletion.
PP4 Not assessed: no individual phenotype or phenotype-specificity evidence was available.
PP5 Not assessed: no ClinVar expert-panel pathogenic or likely-pathogenic assertion for this exact variant was available.
Benign
BA1 Not assessed: no allele frequency data were available, so the BA1 population-frequency threshold could not be evaluated.
BS1 Not assessed: no usable population frequency data were available to compare against the BS1 prevalence threshold.
BS2 Not assessed: no population homozygote observations or carrier disease-status data were available.
BS3 Not assessed: insufficient functional or validated-assay evidence was available to establish a benign effect.
BS4 Not assessed: no family members with known genotypes and phenotypes were reported, and absence of segregation cannot be inferred from missing data.
BP1 Not assessed: this is a 2-bp deletion, not a missense variant, so the missense-specific BP1 rule does not apply.
BP2 Not assessed: no observation of the variant in cis with a pathogenic variant or in trans with a benign variant was available.
BP3 Not assessed: the reading frame and genomic location could not be resolved, so repeat-region context could not be evaluated.
BP4 Not assessed: no computational prediction of any kind was available to support a benign effect.
BP5 Not assessed: no evidence of an alternative molecular diagnosis explaining a reported phenotype was available.
BP6 Not assessed: no ClinVar expert-panel benign or likely-benign assertion for this exact variant was available.
N/A · 1 BP7
Research & evidence
Population frequency
v4.1
This variant is absent from gnomAD v4.1.
v2.1
This variant is absent from gnomAD v2.1.
🇨🇦 CA
This variant is absent from gnomAD-Canada.
Allele frequency by ancestry
three datasets · side by side
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar No data
No ClinVar submissions were recorded for this variant.
In silico No data
No in-silico prediction was recorded for this variant.
Functional No data
No calibrated functional assay or RNA evidence was identified for this variant.
Somatic evidence
COSMIC
This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant cancer hotspot.
Sources & reference links

No sources recorded.